COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study.

Paxlovid (nirmatrelvir/ritonavir) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/42228900

Danielle C Chiang; Edward Ramos; Emily G Spencer; Eric J Topol; Giorgio Quer; Jacqueline K Kueper; Jay A Pandit; Jyothi Purushotham; Kalyani Kottilil; Kristian G Andersen; Leila Roumani; Michael J Mina

Jun 3, 2026